24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Chiasma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:40
Bazan returns to full capacity after Iran’s 2025 strike, despite new missile damage
14:15
Unity shuts down ironSource ad network, selling Supersonic three-and-a-half years after $4.4 billion merger
19:46
Israeli fuze maker Aryt rides arms boom with 300% revenue growth
19:04
“We delivered the Air Force the most advanced defense system in the world, but it does not become operational in one day”
More stories
Buzz
Most popular
Daily
Weekly
1
“We delivered the Air Force the most advanced defense system in the world, but it does not become operational in one day”
2
Iron Dome and Iron Beam developer Rafael targets fast-track IPO at over $20 billion valuation
3
U.S. airlift and local production sustain Israel’s war effort
4
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
5
Unity shuts down ironSource ad network, selling Supersonic three-and-a-half years after $4.4 billion merger
More news
Chiasma
1 stories about Chiasma
Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering
09.04.19
|
CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland